Adoptive T Lymphocyte Administration for Chronic Norovirus Treatment in Immunocompromised Hosts

This is a Phase I dose-escalation study to evaluate the safety of norovirus -specific T-cell (NST) therapy for chronic norovirus infection in participants following hematopoietic stem cell transplantation (HSCT) or who are immunocompromised due to PID and have not undergone HSCT, or Solid Organ Transplant (SOT) recipients.

NCT Number	NCT04691622
Lead Sponsor	Children's National Research Institute
Conditions	Viral Infection, Hematopoietic Stem Cell Transplantation (HSCT), Primary Immunodeficiency Disorders (PID)
Enrollment	48 participants
Start Date	2022-03-17
Primary Completion	2028-08-30 (estimated)
Study Completion	2028-10-30 (estimated)
Updated on ClinicalTrials.gov	2026-01-26